Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Immunity. 2023 Aug 8;56(8):1825-1843.e6. doi: 10.1016/j.immuni.2023.06.017. Epub 2023 Jul 13.
Glioblastoma (GBM), a highly lethal brain cancer, is notorious for immunosuppression, but the mechanisms remain unclear. Here, we documented a temporospatial patterning of tumor-associated myeloid cells (TAMs) corresponding to vascular changes during GBM progression. As tumor vessels transitioned from the initial dense regular network to later scant and engorged vasculature, TAMs shifted away from perivascular regions and trafficked to vascular-poor areas. This process was heavily influenced by the immunocompetence state of the host. Utilizing a sensitive fluorescent UnaG reporter to track tumor hypoxia, coupled with single-cell transcriptomics, we revealed that hypoxic niches attracted and sequestered TAMs and cytotoxic T lymphocytes (CTLs), where they were reprogrammed toward an immunosuppressive state. Mechanistically, we identified chemokine CCL8 and cytokine IL-1β as two hypoxic-niche factors critical for TAM trafficking and co-evolution of hypoxic zones into pseudopalisading patterns. Therefore, perturbation of TAM patterning in hypoxic zones may improve tumor control.
胶质母细胞瘤(GBM)是一种高度致命的脑癌,以免疫抑制而臭名昭著,但具体机制仍不清楚。在这里,我们记录了肿瘤相关髓样细胞(TAMs)在 GBM 进展过程中与血管变化相对应的时空模式。随着肿瘤血管从最初密集的规则网络转变为后来稀疏和充血的血管,TAMs 离开血管周围区域并迁移到血管稀少的区域。这个过程受到宿主免疫能力状态的严重影响。我们利用敏感的荧光 UnaG 报告基因来跟踪肿瘤缺氧,并结合单细胞转录组学,揭示了缺氧龛吸引和隔离 TAMs 和细胞毒性 T 淋巴细胞(CTL),并在那里它们被重新编程为免疫抑制状态。从机制上讲,我们确定趋化因子 CCL8 和细胞因子 IL-1β 是两个关键的缺氧龛因子,对于 TAM 迁移和缺氧区向假栅格模式的共同进化至关重要。因此,干扰缺氧区的 TAM 模式可能会改善肿瘤控制。
Cell Commun Signal. 2024-2-22
Int J Mol Sci. 2021-10-12
Cell Rep Med. 2023-11-21
J Clin Invest. 2023-1-3
Theranostics. 2025-7-11
Trends Pharmacol Sci. 2025-8-9
Cell Death Differ. 2025-6-18
iScience. 2022-12-22
J Am Soc Nephrol. 2022-10
Nature. 2022-7
Nat Rev Cancer. 2021-12
Arthritis Res Ther. 2021-8-14
Nat Rev Cancer. 2021-8
Cancer Discov. 2021-4
Curr Protoc. 2021-3